{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:21:10Z","timestamp":1792552870801,"version":"4.5.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Isavuconazole is a relatively new antifungal agent indicated for the management of various invasive fungal diseases (IFDs), including invasive aspergillosis. Information on real-world experience with isavuconazole is scarce. This retrospective observational study aimed to describe the usage of isavuconazole in clinical practice with an in-depth evaluation of individual isavuconazole exposure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients treated with isavuconazole were evaluated based on retrospective data, including therapeutic drug monitoring (TDM) data and efficacy and safety data. Additionally, we calculated the individual isavuconazole exposure described by the average AUC24 over the first 7\u2005days of treatment by means of non-linear mixed-effects modelling and compared this with the currently desired lower target AUC of 60\u2005mg\u00b7h\/L.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ninety-nine patients treated with isavuconazole were evaluated. In our real-life cohort, isavuconazole was often deployed off-label in patients with non-classical host factors and infections with non-Aspergillus and non-Mucorales species. Isavuconazole was most often chosen for its safety profile, even after prior triazole treatment with manifestations of toxicity. TDM and subsequent dosage adjustments were frequently performed. The individual average AUC24 over 7\u2005days was above 60\u2005mg\u00b7h\/L in 29 out of 77 (37.7%) patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This overview provides practical insights that can aid clinicians in the management of their patients with IFD. Our study shows that isavuconazole was used in a diverse patient population and was well tolerated overall. Individual isavuconazole exposure reflected by the average AUC24 over the first 7 days of treatment was generally low and variable. Dosage adjustments following TDM were frequently performed. Our experience shows that isavuconazole is a feasible alternative after prior azole treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae139","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T20:27:12Z","timestamp":1719520032000},"page":"1801-1810","source":"Crossref","is-referenced-by-count":19,"title":["Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study"],"prefix":"10.1093","volume":"79","author":[{"given":"Mehmet","family":"Erg\u00fcn","sequence":"first","affiliation":[{"name":"Radboudumc\u2014CWZ Center of Expertise for Mycology, Radboud University Medical Center , Nijmegen , The Netherlands"},{"name":"Department of Medical Microbiology, Radboud University Medical Center , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4736-6515","authenticated-orcid":false,"given":"Anouk M E","family":"Jansen","sequence":"additional","affiliation":[{"name":"Radboudumc\u2014CWZ Center of Expertise for Mycology, Radboud University Medical Center , Nijmegen , The Netherlands"},{"name":"Department of Pharmacy, Radboud University Medical Center , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4935-9765","authenticated-orcid":false,"given":"Luuk B","family":"Hilbrands","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Radboud University Medical Center , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0125-9543","authenticated-orcid":false,"given":"Elizabeth","family":"de Kort","sequence":"additional","affiliation":[{"name":"Radboudumc\u2014CWZ Center of Expertise for Mycology, Radboud University Medical Center , Nijmegen , The Netherlands"},{"name":"Department of Haematology, Radboud University Medical Center , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henricus","family":"Kunst","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Dutch Academic Alliance Skull Base Pathology, Radboud University Medical Centre , Nijmegen , The Netherlands"},{"name":"Department of Otorhinolaryngology, Dutch Academic Alliance Skull Base Pathology, Maastricht University Medical Center+ , Maastricht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique H E","family":"Reijers","sequence":"additional","affiliation":[{"name":"Radboudumc\u2014CWZ Center of Expertise for Mycology, Radboud University Medical Center , Nijmegen , The Netherlands"},{"name":"Department of Pulmonology, Radboud University Medical Center , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen A","family":"Schouten","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Radboud University Medical Center , Nijmegen , The Netherlands"},{"name":"Scientific Centre for Quality of Healthcare (IQ healthcare), Radboud Institute for Health Sciences , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8600-9860","authenticated-orcid":false,"given":"Paul E","family":"Verweij","sequence":"additional","affiliation":[{"name":"Radboudumc\u2014CWZ Center of Expertise for Mycology, Radboud University Medical Center , Nijmegen , The Netherlands"},{"name":"Department of Medical Microbiology, Radboud University Medical Center , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-725X","authenticated-orcid":false,"given":"Roger J M","family":"Br\u00fcggemann","sequence":"additional","affiliation":[{"name":"Radboudumc\u2014CWZ Center of Expertise for Mycology, Radboud University Medical Center , Nijmegen , The Netherlands"},{"name":"Department of Pharmacy, Radboud University Medical Center , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,27]]},"reference":[{"key":"2024073123503958700_dkae139-B1","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1056\/NEJMra2027424","article-title":"Aspergillus infections","volume":"385","author":"Thompson","year":"2021","journal-title":"N Engl J Med"},{"key":"2024073123503958700_dkae139-B2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","article-title":"Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study","volume":"6","author":"Schauwvlieghe","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2024073123503958700_dkae139-B3","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2024073123503958700_dkae139-B4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"2024073123503958700_dkae139-B5","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/AAC.04569-14","article-title":"Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study","volume":"59","author":"Cornely","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123503958700_dkae139-B6","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2024073123503958700_dkae139-B7","doi-asserted-by":"crossref","first-page":"e0029021","DOI":"10.1128\/AAC.00290-21","article-title":"Safety, tolerability, and population pharmacokinetics of intravenous and oral isavuconazonium sulfate in pediatric patients","volume":"65","author":"Arrieta","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"2024073123503958700_dkae139-B8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2024073123503958700_dkae139-B9","doi-asserted-by":"crossref","first-page":"e01034-17","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123503958700_dkae139-B10","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/AAC.04907-14","article-title":"Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model","volume":"59","author":"Seyedmousavi","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123503958700_dkae139-B11","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024073123503958700_dkae139-B12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1164\/rccm.201111-1978OC","article-title":"A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients","volume":"186","author":"Blot","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2024073123503958700_dkae139-B13","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s00134-020-06091-6","article-title":"Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion","volume":"46","author":"Verweij","year":"2020","journal-title":"Intensive Care Med"},{"key":"2024073123503958700_dkae139-B14","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024073123503958700_dkae139-B15","author":"EMA"},{"key":"2024073123503958700_dkae139-B16","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123503958700_dkae139-B17","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/cid\/ciy827","article-title":"Isavuconazole versus caspofungin in the treatment of candidemia and other invasive Candida infections: the ACTIVE trial","volume":"68","author":"Kullberg","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024073123503958700_dkae139-B18","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Bruggemann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2024073123503958700_dkae139-B19","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s40262-023-01305-8","article-title":"Population pharmacokinetics of total and unbound isavuconazole in critically ill patients: implications for adaptive dosing strategies","volume":"62","author":"Jansen","year":"2023","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/8\/1801\/58688865\/dkae139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/8\/1801\/58688865\/dkae139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T05:50:11Z","timestamp":1722491411000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/8\/1801\/7700653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,27]]},"references-count":19,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4,27]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae139","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,4,27]]}}}